Johnson & Johnson (NYSE:JNJ) Holdings Lowered by Weatherly Asset Management L. P.

Weatherly Asset Management L. P. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.7% in the 4th quarter, HoldingsChannel reports. The firm owned 33,324 shares of the company’s stock after selling 2,772 shares during the quarter. Weatherly Asset Management L. P.’s holdings in Johnson & Johnson were worth $4,819,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Wealthcare Capital Partners LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $480,000. Sovran Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $3,288,000. Peterson Wealth Services lifted its stake in Johnson & Johnson by 5.4% in the 4th quarter. Peterson Wealth Services now owns 13,111 shares of the company’s stock worth $1,896,000 after acquiring an additional 669 shares in the last quarter. Stonebridge Financial Group LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $4,817,000. Finally, BostonPremier Wealth LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $659,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Guggenheim increased their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley reduced their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Finally, Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $156.20 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market capitalization of $376.08 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business has a 50 day simple moving average of $147.73 and a 200 day simple moving average of $156.01.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.